The differences between patients with malignant childhood leukemia were revealed by the observational genetics

independent study published recently by the University of New York identified three new subgroups (JMML) of young granulocytes, monocyte leukemia, that can predict patient outcomes, including those most likely to have the disease subside on its own.
granulocyte-monocyte leukemia (JMML) is a malignant childhood cancer with limited treatment. Current JMML clinical and genetic markers do not explain the different clinical outcomes associated with the disease. DNA methylation plays an important role in the disease. Two independent studies have shown that this oscic genetic marker may help explain differences in outcomes in different JMML patients. Christopher Plass, Daniel Lipka and colleagues at the German Cancer Research Centre in Heidelberg analyzed DNA methylation patterns and mutations in 167 JMML samples and found three subgroups with different levels of methylation (high, medium, and low). In patients with high levels of methylation, poor clinical outcomes, patients with low levels of methylation had good prognosmation, and mutations in all three groups were different, indicating an association between the activation of DNA methylation mechanisms and mutation patterns in JMML patients. Elliot Stieglitz and Mignon Loh of the University of California, San Francisco, and colleagues studied DNA methylation in 39 patients and independently identified three DNA methylation subgroups, where high methylation levels were associated with poor clinical outcomes and low methylation levels were associated with good prognosmation;
this study provides the basis for dividing different JMML patients according to DNA methylation, and helps people to better understand the basic biological mechanisms of JMML. (Source: Science Network, Princess Feng)